Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Drug Insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 465–474 (2005)Cite this article

Abstract

In Europe, the use of interventional cardiology, including percutaneous coronary intervention (PCI), is increasing rapidly. The use of anticoagulation agents in PCI procedures is essential, but despite technical improvements, a significant associated bleeding risk still exists: more than 5% of patients are estimated to require transfusion, and around a further 13% experience minor bleeding. The methods used to detect and measure blood loss following PCI, however, vary widely between institutions and clinical trials. The risk of bleeding is influenced by therapeutic options and patient-specific characteristics, such as age, anemia and previous exposure to anticoagulants. Bleeding is associated with death, and also with less severe conditions such as thrombocytopenia, anemia, and hematoma, which have major impacts on patients' welfare and length of hospital stay, and on hospital budgets. Unfractionated heparin is the most widely used anticoagulant during PCI. Heparin, antiplatelet agents and other anticoagulants, however, have limitations that make it difficult to achieve a level of anticoagulation that prevents ischemic events without promoting bleeding. The use of low-molecular-weight heparin and the addition of glycoprotein IIb/IIIa inhibitors offer improved outcomes, but safer and more effective therapeutic agents are still required. New anticoagulants, including direct thrombin inhibitors such as bivalirudin, show similar levels of efficacy to heparin plus glycoprotein IIb/IIIa inhibitors, but with fewer hemorrhagic complications, and might advance clinical practice. This review evaluates the impact of PCI-related bleeding on patients' outcomes and hospital resources, examines methods for the detection and measurement of bleeding, and appraises the therapeutic options—particularly the newer agents—available to minimize hemorrhagic complications.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Frequency of percutaneous coronary intervention-related bleeding complications, by type and in relation to mortality.6

Similar content being viewed by others

References

  1. Weitz JI and Bates SM (2000) Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction. Arch Intern Med 160: 749–758

    Article  CAS  Google Scholar 

  2. Silber S et al. (2005) Guidelines for percutaneous coronary interventions. Eur Heart J 26: 804–847

    Article  Google Scholar 

  3. Patrono C et al. (2004) Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 25: 166–181

    Article  Google Scholar 

  4. Topol EJ et al. (1993) Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 87: 1622–1629

    Article  CAS  Google Scholar 

  5. Lopez LM (2003) Clinical challenges of bleeding in percutaneous coronary intervention. Am J Health-Syst Pharm 60 (Suppl 3): S8–S14

    Article  Google Scholar 

  6. Kinnaird TD et al. (2003) Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92: 930–935

    Article  Google Scholar 

  7. Lauer MA et al. (2002) Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997. Am J Cardiol 89: 924–929

    Article  Google Scholar 

  8. Rao AK et al. (1988) Thrombolysis in Myocardial Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11: 1–11

    Article  CAS  Google Scholar 

  9. Berkowitz SD et al. (1997) Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 95: 2508–2516

    Article  CAS  Google Scholar 

  10. Maroo A and Lincoff AM (2004) Bivalirudin in PCI: an overview of the REPLACE-2 trial. Semin Thromb Hemost 30: 329–336

    Article  CAS  Google Scholar 

  11. Berkowitz SD et al. (2001) Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol 88: 1230–1234

    Article  CAS  Google Scholar 

  12. Goodman SG et al. (2003) Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 107: 238–244

    Article  CAS  Google Scholar 

  13. Stone GW et al. (2004) Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 148: 764–775

    Article  Google Scholar 

  14. Moscucci M (2002) Frequency and costs of ischemic and bleeding complications after percutaneous coronary interventions: rationale for new antithrombotic agents. J Invasive Cardiol 14 (Suppl B): 55B–64B

    PubMed  Google Scholar 

  15. Montalescot G et al. (2005) Description of modern practices of percutaneous coronary intervention and identification of risk factors for adverse outcome in the French nationwide OPEN registry. Heart 91: 89–90

    Article  CAS  Google Scholar 

  16. Lincoff AM et al. (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289: 853–863

    Article  CAS  Google Scholar 

  17. Moscucci M et al. (2003) Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE) Eur Heart J 24: 1815–1823

    Article  CAS  Google Scholar 

  18. Nikolsky E et al. (2004) Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol 44: 1200–1209

    PubMed  Google Scholar 

  19. Koreny M et al. (2004) Arterial puncture closing devices compared with standard manual compression after cardiac catheterization. Systematic review and meta-analysis. JAMA 291: 350–357

    Article  CAS  Google Scholar 

  20. Saghir T et al. (2003) Transradial diagnostic and percutaneous coronary intervention. J Coll Physicians Surg Pak 13: 242–247

    PubMed  Google Scholar 

  21. Louvard Y et al. (2004) Comparison of transradial and transfemoral approaches for coronary angiography and angioplasty in octogenarians (the OCTOPLUS study). Am J Cardiol 94: 1177–1180

    Article  Google Scholar 

  22. Agostoni P et al. (2004) Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures: systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol 44: 349–356

    Article  Google Scholar 

  23. Kassam S et al. (2004) Radial versus femoral access for rescue percutaneous coronary intervention with adjuvant glycoprotein IIb/IIIa inhibitor use. Can J Cardiol 20: 1439–1442

    PubMed  Google Scholar 

  24. Mann T et al. (1998) Stenting in acute coronary syndromes: a comparison of radial versus femoral access sites. J Am Coll Cardiol 32: 572–576

    Article  CAS  Google Scholar 

  25. Smith SC Jr et al. (2001) ACC/AHA guidelines for percutaneous coronary intervention (Revision of the 1993 PTCA guidelines): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 37: 2239i–2239ixvi

    Article  Google Scholar 

  26. Chew DP et al. (2005) Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 95: 581–585

    Article  CAS  Google Scholar 

  27. Rao SV et al. (2004) Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292: 1555–1562

    Article  CAS  Google Scholar 

  28. Milkovich G and Gibson G (2003) Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention. Am J Health Syst Pharm 60 (Suppl 3): S15–S21

    Article  Google Scholar 

  29. Cohen DJ et al. (2004) Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 44: 1792–1800

    CAS  Google Scholar 

  30. Becker DL et al. (1999) Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J Biol Chem 274: 6226–6233

    Article  CAS  Google Scholar 

  31. Bates SM and Weitz JI (2000) The mechanism of action of thrombin inhibitors. J Invasive Cardiol 12 (Suppl F): 27F–32F

    PubMed  Google Scholar 

  32. Popma JJ et al. (2004) Antithrombotic therapy during percutaneous coronary intervention: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl 3): 576S–599S

    Article  CAS  Google Scholar 

  33. Popma JJ et al. (2001) Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 119: 321S–336S

    Article  CAS  Google Scholar 

  34. Tolleson TR et al. (2003) Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention. J Am Coll Cardiol 41: 386–393

    Article  CAS  Google Scholar 

  35. Chew DP et al. (2001) Defining the optimal activated clotting time during percutaneous coronary intervention. Circulation 103: 361–966

    Google Scholar 

  36. Hirsh J (1991) Heparin. N Engl J Med 324: 1565–1574

    Article  CAS  Google Scholar 

  37. Klein W et al. (2003) Patterns of use of heparins in ACS. Correlates and hospital outcomes: the Global Registry of Acute Coronary Events (GRACE). Thromb Haemost 90: 519–527

    Article  CAS  Google Scholar 

  38. Ferguson JJ et al. (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292: 45–54

    CAS  PubMed  Google Scholar 

  39. Borentain M et al. (2005) Low-molecular-weight heparin vs unfractionated heparin in percutaneous coronary intervention: a combined analysis. Catheter Cardiovasc Interv 65: 212–221

    Article  Google Scholar 

  40. Mehta SR et al. (2005) Arixtra® study in percutaneous coronary intervention: a randomised evaluation (ASPIRE) pilot trial. Circulation 111: 1390–1397

    Article  CAS  Google Scholar 

  41. Warkentin TE et al. (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332: 1330–1335

    Article  CAS  Google Scholar 

  42. Campbell KR et al. (2000) Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 12 (Suppl F): 14F–9

    PubMed  Google Scholar 

  43. Singer RL et al. (1993) Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass. Chest 104: 1436–1440

    Article  CAS  Google Scholar 

  44. British Cardiovascular Intervention Society (2003) British Cardiovascular Intervention Society audit [http://www.bcis.org.uk/resources/audit/audit2003] (accessed 10 May 05)

  45. de Queiroz Fernandes Araújo JO et al. (2004) Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials. Am Heart J 148: 937–943

    Article  Google Scholar 

  46. Brener SJ et al. (1998) Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98: 734–741

    Article  CAS  Google Scholar 

  47. De Luca G et al. (2005) Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293: 1759–1765

    Article  CAS  Google Scholar 

  48. Boeynaems JM et al. (2005) P2Y receptor antagonists in thrombosis. Curr Opin Investig Drugs 6: 275–282

    CAS  PubMed  Google Scholar 

  49. Herbert JM et al. (2003) P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med 3: 113–122

    Article  Google Scholar 

  50. van Giezen JJ et al. (2005) Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 31: 195–204

    Article  CAS  Google Scholar 

  51. Nemergut C and Cheng JWM (2000) Use of direct thrombin inhibitors in acute coronary syndrome. Clin Ther 22: 937–948

    Article  CAS  Google Scholar 

  52. European Medicines Agency (2005) [http://www.emea.eu.int/index/indexh1.htm] (accessed 10 May 05)

  53. Hirahara T et al. (2004) Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction. J Cardiol 44: 47–52

    PubMed  Google Scholar 

  54. Bittl JA et al. (2001) Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 142: 952–959

    Article  CAS  Google Scholar 

  55. Kong DF et al. (1999) Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 100: 2049–2053

    Article  CAS  Google Scholar 

  56. Lincoff AM et al. (2004) Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292: 696–703

    Article  CAS  Google Scholar 

  57. Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet and Anti-Thrombotic Agents. [http://www.timi.org/home.htm] (accessed 22 July 2005)

  58. Collet JP et al. (2005) Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events Eur Heart J [doi:10.1093/eurheartj/ehi337]

  59. Hulot JS et al. (2005) Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 77: 542–552

    Article  CAS  Google Scholar 

  60. Berger PB et al. 2005. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J 149: 869–75

    Article  CAS  Google Scholar 

  61. Chew DP et al. (2003) Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 92: 919–923

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Professor of Interventional Cardiology at the London Chest Hospital, Barts and the London NHS Trust, London, UK

    Martin T Rothman

Authors
  1. Martin T Rothman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin T Rothman.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rothman, M. Drug Insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options. Nat Rev Cardiol 2, 465–474 (2005). https://doi.org/10.1038/ncpcardio0311

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0311

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing